A first‐in‐human, single and multiple dose study of lunsekimig, a novel anti‐TSLP/anti‐IL‐13 NANOBODY® compound, in healthy volunteers

• Main Authors: Annemie Deiteren (Author), Lieselot Bontinck (Author), Griet Conickx (Author), Marie Vigan (Author), Nele Dervaux (Author), Matthieu Gassiot (Author), Selcuk Bas (Author), Benjamin Suratt (Author), Heribert Staudinger (Author), Emmanuel Krupka (Author)
• Format: Book
• Published: Wiley, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Lunsekimig is a novel, bispecific NANOBODY® molecule that inhibits both thymic stromal lymphopoietin (TSLP) and interleukin (IL)‐13, two key mediators of asthma pathophysiology. In this first‐in‐human study, we evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD)...